html
Sinovac’s Three‑Shot Mystery: Why Omicron Still Snags Those Antibodies
Picture this: You’ve got three syrupy injections of Sinovac’s CoronaVac, a vaccine that’s been knights in shining armor for many in China. But according to a fresh report hailing from the University of Hong Kong and the Chinese University of Hong Kong, even three doses might not be enough to chase the elusive Omicron variant away.
Fizzles and Fails
- Sinovac’s trio leaves the immune system a bit short of the punch it needs to fight Omicron.
- In sharp contrast, Pfizer‑BioNTech’s bonus shot—courtesy of a third dose following two of the same or Sinovac’s—achieves “protective levels” of antibodies.
- Laboratory tests confirm the Pfizer‑BioNTech combo neutralizes Omicron, proving it’s got the upper hand.
Beyond the Numbers
The study’s back‑room data and exact sample size remain shrouded in mystery—as if those back‑office sleuths kept the participant count under a sluicegate. The researchers, funded by the Health and Medical Research Fund and the Hong Kong Government, have pointed the finger at Sinovac’s shortcomings without a signial apology from the company (yet).
Who’s on the Vaccine Menu?
In China, the two star players are Sinovac’s CoronaVac and state‑run Sinopharm’s BBIBP‑CorV, the birth‑dated duo exporting vaccine numbers worldwide. Meanwhile, Hong Kong’s policy is a mix—Sinovac and Pfizer‑BioNTech get the popular shots, but 12‑to‑17‑year‑olds snag only the latter.
Looking Ahead
With the age‑specific rollout, Hong Kong’s parents are urged to keep the BioNTech option on hand—maybe even consider a “small‑dose” future. The bottom line? A third dose appears to be the game‑changer, especially when fighting the ever‑mysterious Omicron.
